MA33676B1 - Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevée - Google Patents

Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevée

Info

Publication number
MA33676B1
MA33676B1 MA34780A MA34780A MA33676B1 MA 33676 B1 MA33676 B1 MA 33676B1 MA 34780 A MA34780 A MA 34780A MA 34780 A MA34780 A MA 34780A MA 33676 B1 MA33676 B1 MA 33676B1
Authority
MA
Morocco
Prior art keywords
cholecalciferol
salts
acids
high dose
diphenylphosphonate
Prior art date
Application number
MA34780A
Other languages
Arabic (ar)
English (en)
Inventor
Jin-Sun Kim
Geun-Hyeog Lee
Byong-Sun Choi
Jae-Shin Kim
Jin-Ha Park
Mi-Jin O
Eun-Mi Kim
Original Assignee
Hanlim Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanlim Pharmaceutical Co Ltd filed Critical Hanlim Pharmaceutical Co Ltd
Publication of MA33676B1 publication Critical patent/MA33676B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur des compositions pharmaceutiques pour empêcher ou traiter l'ostéoporose, qui comprennent des composés à base de bisphosphonate tels que les acides risédroniques ou leurs sels, les acides ibandroniques ou leurs sels, ou similaires, et du cholécalciférol à haute dose, et qui doivent être administrés une fois par mois. La présente invention porte également sur des compositions pharmaceutiques pour empêcher ou traiter l'ostéoporose, devant être administrées une fois par mois, comprenant : (a) des granulés contenant du cholécalciférol obtenus par adsorption, sur de la cellulose microcristalline, de la solution obtenue par dissolution, dans l'éthanol ou une solution aqueuse d'éthanol de : (i) 24 000 à 50 000 ui de cholécalciférol ; (ii) un ou plusieurs premiers stabilisants choisis parmi l'acétate de tocophéryle, l'hydroxytoluène butylé et l'hydroxyanisole butylé ; et (iii) un liant ; (b) du mannitol comme second stabilisant ; et (c) des acides risédroniques ou leurs sels ou des acides ibandroniques ou leurs sels.
MA34780A 2009-09-18 2012-04-16 Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevée MA33676B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090088480A KR101102364B1 (ko) 2009-09-18 2009-09-18 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
PCT/KR2010/003920 WO2011034274A2 (fr) 2009-09-18 2010-06-17 Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevée

Publications (1)

Publication Number Publication Date
MA33676B1 true MA33676B1 (fr) 2012-10-01

Family

ID=43759131

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34780A MA33676B1 (fr) 2009-09-18 2012-04-16 Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevée

Country Status (8)

Country Link
EP (1) EP2478909B1 (fr)
KR (1) KR101102364B1 (fr)
CN (2) CN102497867B (fr)
BR (1) BR112012003907A2 (fr)
MA (1) MA33676B1 (fr)
MX (1) MX343184B (fr)
RU (1) RU2533230C2 (fr)
WO (1) WO2011034274A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
ITMI20120393A1 (it) * 2012-03-14 2013-09-15 Tiberio Bruzzese Formulazioni acquose di bisfosfonati, vitamina d e alcol benzilico adatte all'uso intramuscolare o sottocutaneo
MX350569B (es) * 2012-12-03 2017-09-11 Landsteiner Scient S A De C V Composicion farmaceutica estable para el tratamiento de osteoporosis.
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
KR20160144663A (ko) 2015-06-09 2016-12-19 최숙 제제 및 이의 제조방법
IT201600123773A1 (it) * 2016-12-06 2018-06-06 Abiogen Pharma Spa Composizione per il trattamento dell’osteoartrosi
CN108420797B (zh) * 2018-05-09 2022-05-03 南京海融制药有限公司 维生素d类似物制剂及其制备方法
KR102158375B1 (ko) * 2018-10-25 2020-09-21 단국대학교 천안캠퍼스 산학협력단 비타민 d 에멀젼 및 비스포스포네이트를 포함하는 복합 액상 제형 및 이의 골다공증 예방 또는 치료 용도
KR102211287B1 (ko) * 2018-12-21 2021-02-03 (주)휴온스 비타민 d 또는 이의 유도체를 포함하는 안정성이 개선된 액상 제제
CN117205170A (zh) * 2023-10-08 2023-12-12 广州汇元医药科技有限公司 一种提高维生素d3均匀度与稳定性的碳酸钙d3片剂的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2963718B2 (ja) * 1990-03-06 1999-10-18 グレラン製薬株式会社 ビタミンｄ▲下３▼類含有製剤
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
KR100317935B1 (ko) 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
US20030072802A1 (en) * 2001-10-11 2003-04-17 R.T. Alamo Ventures, Inc. Sustained release topiramate
US20050070504A1 (en) 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
GB0330009D0 (en) * 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
CN1993134A (zh) 2004-05-19 2007-07-04 默克公司 用于抑制骨吸收含有二膦酸（阿仑膦酸）和维生素d（胆钙化固醇）的组合物
US20050261250A1 (en) 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
KR20050110814A (ko) 2004-05-19 2005-11-24 머크 앤드 캄파니 인코포레이티드 골 흡수를 억제하기 위한 조성물 및 방법
WO2008026907A1 (fr) * 2006-08-29 2008-03-06 Espinosa Abdala Leopoldo De Je Compositions pharmaceutiques comprenant des bisphosphonates et des vitamines en vue de leur administration hebdomadaire et bimensuelle
KR100822133B1 (ko) 2006-11-06 2008-04-15 한미약품 주식회사 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제
KR100844256B1 (ko) * 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
MX2012002786A (es) 2012-06-25
MX343184B (es) 2016-10-26
KR20110030852A (ko) 2011-03-24
CN102497867B (zh) 2015-04-29
EP2478909B1 (fr) 2018-04-25
KR101102364B1 (ko) 2012-01-03
WO2011034274A3 (fr) 2011-05-19
WO2011034274A2 (fr) 2011-03-24
CN102497867A (zh) 2012-06-13
RU2012109614A (ru) 2013-10-27
RU2533230C2 (ru) 2014-11-20
EP2478909A2 (fr) 2012-07-25
CN103191138A (zh) 2013-07-10
BR112012003907A2 (pt) 2016-03-22
EP2478909A4 (fr) 2014-02-26

Similar Documents

Publication Publication Date Title
MA33676B1 (fr) Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevée
MA46997B1 (fr) Préparation de complexes solides de cyclodextrine permettant une administration de substance pharmaceutique active ophtalmique
EP2588116A4 (fr) Formulations d'une solution intraveineuse de posaconazole stabilisées par une cyclodextrine bêta substituée
MA30766B1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
MA32497B1 (fr) Composes et compositions en tant qu'inhibiteurs de kinase
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
UA96302C2 (en) Solid dosage form comprising 2-ethoxy-1-{[2'-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]methyl}-1h-benzimidazole-7-carboxylic acid
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
MA31898B1 (fr) Compositions pharmaceutiques
MA32385B1 (fr) Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un derive d'indolinone
MA34837B1 (fr) Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla)
MA31497B1 (fr) Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
EP2078731A4 (fr) Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
MA34296B1 (fr) Composition retard injectable antipsychotique
CL2007001388A1 (es) Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer.
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0514766A (pt) composições farmacêuticas
EP1750862A4 (fr) Composition pharmaceutique contenant de l'irbesartan
MA34313B1 (fr) Formulation pharmaceutique sous la forme de comprimés bicouches comprenant un inhibiteur de hmg-coa réductase et d'irbésartan
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
CO6321158A2 (es) Formulacion oral
MA38694B1 (fr) Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase
DE602005027727D1 (de) Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
UA122762C2 (uk) Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін'єкцій, застосування та спосіб приготування фармацевтичної композиції